Publication
CDK4/6 inhibition is more active against the glioblastoma proneural subtype.
Authors not recorded
Oncotarget2017PMID 28903422PMC5589661stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- drugPalbociclibcivic_curation1.00
- geneCDK6civic_curation1.00
- variantCDK6 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28903422
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CDK6 Overexpression1 | ||||||||
| Palbociclib | Glioblastoma Proneural SubtypeUNRESOLVED | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID7800In this study twelve GBM cell lines and normal human astrocytes (NHA) were treated with the CDK4/6 inhibitor palbociclib. NHA and several GBM cell lines were resistant to palbociclib with IC50 values … (full text at CIViC) PMID 28903422 · Li et al., 2017 · Open in CIViC | civic |